Phaseline

Companies › D3 Bio (Wuxi)

D3 Bio (Wuxi): clinical trials, targets and expected readouts

5 active drug programs in 5 registered trials: 5 Phase 1; Oncology, Other; next expected readout Apr 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
D3S-001
KRAS G12C inhibitor
KRASPhase 1KRAS P.G12CApr 2027
D3L-002
Bispecific antibody targeting TIGIT and PVRIG
TIGIT, PVRIGPhase 1Advanced Solid TumorNov 2027
D3S-003
KRAS G12D inhibitor
KRASPhase 1KRAS P.G12DJan 2028
D3S-002
MAPK pathway inhibitor
–Phase 1Advanced Solid Tumors With MAPK Pathway MutationsAug 2028
D3L-001
Anti-HER2 antibody
ERBB2Phase 1HER-2 Positive Advanced Solid TumorsDec 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05410145D3S-001Phase 1KRAS P.G12COncologyApr 2027
NCT07667842D3L-002Phase 1Advanced Solid TumorOncologyNov 2027
NCT07456046D3S-003Phase 1KRAS P.G12DOtherJan 2028
NCT05886920D3S-002Phase 1Advanced Solid Tumors With MAPK Pathway MutationsOncologyAug 2028
NCT05957536D3L-001Phase 1HER-2 Positive Advanced Solid TumorsOncologyDec 2028

Targets

KRAS (2) TIGIT (1) PVRIG (1) ERBB2 (1)

Companies with the same targets

Roche Beijing Biotech Revolution Medicines Jiangsu HengRui Medicine TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) Quanta Therapeutics Pfizer Eli Lilly Chia Tai Tianqing Pharmaceutical Group Boehringer Ingelheim

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.